Skip to main content

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

The Original Article was published on 28 April 2021

Correction to: J Hematol Oncol (2021) 14:71 https://doi.org/10.1186/s13045-021-01081-7

The original article [1] contains errors in Figure 3i, Figure 6c and Figure S9:

  1. 1.

    In Fig. 3i, the legends of the line chart were marked incorrectly.

    Fig. 3
    figure3

    i Immunofluorescence analysis of co-localization between LA (green, FITC) and different subcellular compartments (red, early endosome, lysosome or endoplasmic reticulum) in immature DCs (blue, DAPI, nuclear) (n = 3)

  2. 2.

    In Fig. 6c, the panel of ISA CD8a+ group was unintentionally duplicated onto the panel of YL-ISA NK1.1+ group.

    Fig. 6
    figure6

    c Representative immunohistochemical staining of CD8a and NK1.1 in subcutaneously transplanted tumour tissues

  3. 3.

    In Figure S9, the panel of LA-ISA Liver group was misused.

The corrected figures are presented ahead, and the changes do not affect the conclusions of the paper.

Reference

  1. 1.

    Yu Z, Liu W, He Y, Sun M, Yu J, Jiao X, Han Q, Tang H, Zhang B, Xian Y, et al. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine. J Hematol Oncol. 2021;14(1):71. https://doi.org/10.1186/s13045-021-01081-7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Rui Zhang, Jianping Li or Minjie Wei.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yu, Z., Liu, W., He, Y. et al. Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine. J Hematol Oncol 14, 158 (2021). https://doi.org/10.1186/s13045-021-01176-1

Download citation